Evidence map›Paper›PMID 42274081›Full record

ReviewBritish journal of clinical pharmacology2026

Tobramycin pharmacokinetic and pharmacodynamic targets in people with cystic fibrosis.

Kiera H Harwood, Sarah Bannister, Stephen Duffull, April Martinez, Sarath Ranganathan, Shivanthan Shanthikumar, Amanda Gwee

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kiera H HarwoodDepartment of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia.ORCID https://orcid.org/0009-0006-9507-2497
Sarah BannisterMurdoch Children's Research Institute, Antimicrobials Group, Melbourne, Victoria, Australia.
Stephen DuffullCertara, Princeton, New Jersey, USA.
April MartinezMurdoch Children's Research Institute, Antimicrobials Group, Melbourne, Victoria, Australia.
Sarath RanganathanDepartment of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia.
Shivanthan ShanthikumarDepartment of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia.
Amanda GweeDepartment of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0003-4016-8986

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intravenous tobramycin is a first-line treatment for Pseudomonas aeruginosa infection in people with cystic fibrosis (CF). Tobramycin exhibits concentration-dependent activity; however, excess drug exposure can lead to nephrotoxicity and ototoxicity. While dosing typically targets serum peak (C

Indexed as

Anti-Bacterial AgentsCystic FibrosisPseudomonas InfectionsTobramycinArea Under CurveDose-Response Relationship, DrugHumansOtotoxicityPseudomonas aeruginosaAnti-Bacterial AgentsTobramycinaminoglycosidescystic fibrosispharmacodynamicspharmacokinetics

Identifiers

PMID42274081
PMCPMC13519771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.